Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema
October 13, 2021 08:00 ET
|
Alimera Sciences, Inc.
PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to...
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
September 02, 2021 16:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to...
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
August 24, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Announces Second Quarter 2021 Financial Results
August 13, 2021 08:00 ET
|
Alimera Sciences, Inc.
Consolidated Net Revenue of $21.7 Million up 117% vs. Second Quarter of 2020Consolidated Net Product Revenue of $10.7 Million up 7% vs. Second Quarter of 2020Net Income of $7.6 Million vs. Net Loss of...
Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update
August 10, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®
August 09, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today...
Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
May 27, 2021 08:15 ET
|
Alimera Sciences, Inc.
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
May 17, 2021 08:12 ET
|
Alimera Sciences, Inc.
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced...
Alimera Sciences Announces First Quarter 2021 Financial Results
April 28, 2021 16:32 ET
|
Alimera Sciences, Inc.
ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate Update
April 22, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, April 22, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription...